Everolimus leads to a lower risk of BKV viremia than mycophenolic acid inde novorenal transplantation patients: a single-center experience

Polyomavirus BK Replication inDe NovoKidney Transplant Patients Receiving Tacrolimus or Cyclosporine: A Prospective, Randomized, Multicenter Study

(2012) H. H. Hirsch et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials

(2011) D. C. Brennan et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses

(2010) I. R. Ferrer et al.   JOURNAL OF IMMUNOLOGY

Anti-BK Virus Mechanisms of Sirolimus and Leflunomide Alone and in Combination: Toward a New Therapy for BK Virus Infection

(2010) Abdelhamid Liacini et al.   TRANSPLANTATION

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

Everolimus With Very Low-Exposure Cyclosporine A in De Novo Kidney Transplantation: A Multicenter, Randomized, Controlled Trial

(2009) Maurizio Salvadori et al.   TRANSPLANTATION